{
    "name": "galcanezumab",
    "comment": "Rx",
    "other_names": [
        "Emgality",
        "galcanezumab-gnlm"
    ],
    "classes": [
        "CGRP Monoclonal Antibodies",
        "Antimigraine Agents"
    ],
    "source": "https://reference.medscape.com/drug/emgality-galcanezumab-1000236",
    "pregnancy": {
        "common": [
            "There is pregnancy exposure registry that monitors pregnancy outcomes in women receiving therapy during pregnancy; healthcare providers are encouraged to register pregnant patients, or pregnant women may enroll themselves in the registry by calling 1-833-464-4724 or by contacting the company at ",
            "There are no available data regarding use in pregnant women"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "Administration to rats and rabbits during the period of organogenesis or to rats throughout pregnancy and lactation at plasma exposures greater than that expected clinically did not result in adverse effects on development"
                ]
            },
            {
                "type": "Clinical considerations",
                "description": [
                    "Published data suggests that women with migraine may be at increased risk of preeclampsia during pregnancy"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human milk",
            "The development and health benefits of breastfeeding should be considered along with the motherâ€™s clinical need for the drug and any potential adverse effects on the breastfed child or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "History of serious hypersensitivity reactions to drug or excipients"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hypersensitivity reactions (eg, rash, urticaria, dyspnea) reported; may occur days after administration and may be prolonged; discontinue administration and initiate appropriate therapy if serious reaction occurs",
                "Cases of anaphylaxis and angioedema reported in postmarketing setting; hypersensitivity reactions can occur days after administration and may be prolonged"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Injection site reactions",
            "percent": "18"
        },
        {
            "name": "Hypersensitivity",
            "percent": null
        },
        {
            "name": "Immune system disorders",
            "percent": null
        },
        {
            "name": "Anaphylaxis",
            "percent": null
        },
        {
            "name": "angioedema",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        }
    ]
}